Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina reported third-quarter 2021 results featuring revenues of $1,108 million, a 40% increase year-over-year. GAAP net income was $317 million ($2.08 per diluted share), boosted by a $900 million gain from GRAIL. Non-GAAP earnings were $221 million ($1.45 per diluted share). R&D expenses rose to $436 million, while SG&A expenses surged to $879 million. Despite operational cash flow of $(272) million, Illumina anticipates revenue growth of approximately 36% for 2021. Meanwhile, the GRAIL acquisition is expected to drive market expansion.
Illumina (NASDAQ: ILMN) announced its sequencing and bioinformatics solutions are being used by HostSeq, part of Canada's COVID-19 Genomics Network, to analyze the genetic factors affecting COVID-19 susceptibility by sequencing genomes from up to 10,000 patients. This initiative aims to identify biomarkers to predict severe disease and assist in developing therapeutics. Illumina's Connected Analytics platform will ensure secure data sharing among researchers across Canada's leading facilities, supporting the HostSeq and VirusSeq programs. These efforts are crucial for public health insights and guiding COVID-19 responses.
Illumina (NASDAQ: ILMN) announced a collaboration with Israel's Ministry of Health for a pilot program implementing whole-genome sequencing (WGS) in NICUs for critically-ill infants suspected of genetic disorders. The initiative, starting this month, spans 18 hospitals and aims to provide faster diagnostics by replacing traditional tests. The program may lead to national reimbursement for WGS in Israel, enhancing clinical management and reducing NICU stays. Experts highlight the potential for improved decision-making in urgent neonatal situations.
Summary not available.
Vizgen has appointed Dale Levitzke as Senior Vice President of Global Sales and Support, aiming to enhance its commercial reach for the MERSCOPE Platform.
Levitzke, with nearly 20 years in diagnostics sales, previously led NanoString's revenue growth from under $10MM to over $125MM. His experience will help Vizgen navigate the global market and expand distribution channels in 2022.
The MERSCOPE Platform offers significant insights into spatial genomics, with early uptake at leading institutions, reflecting strong demand in the burgeoning field of spatial biology.
Illumina has appointed Bob Ragusa as the new CEO of GRAIL, effective immediately, focusing on multi-cancer early detection. Ragusa, with over 30 years in genomics and previously Illumina's COO, aims to scale GRAIL and enhance its cancer detection test, Galleri. He takes over from Hans Bishop, who steps down after leading GRAIL since June 2019 and will continue as an advisor until the end of 2021. Illumina emphasizes Ragusa's track record in operational excellence, aiming for growth and innovation in cancer diagnostics.
Illumina, Inc. (NASDAQ:ILMN) will release its third quarter 2021 financial results on November 4, 2021, after market close. A conference call with CEO Francis deSouza and CFO Sam Samad is scheduled for the same day at 2:00 PM PT (5:00 PM ET) to discuss the results. Participants can access the call via Illumina's website or by dialing the provided numbers. A replay will be available for 30 days. Illumina continues to lead in DNA sequencing and genomics, serving various markets including life sciences and oncology.
Illumina (NASDAQ: ILMN) has established two new entities, Illumina Colombia S.A.S. and Illumina México Productos de Biotecnología, to enhance genomics support in Latin America. This initiative follows significant investment and growth in the region. General Manager Nicole Berry emphasized Colombia’s status as South America’s second-largest country and highlighted Mexico as a key market for Illumina. These entities aim to advance clinical services in local healthcare systems, ensuring customers receive optimal training and support for their genomic instruments.
Illumina (NASDAQ: ILMN) has announced findings from the NICUSeq Randomized Time-Delayed Trial, indicating that clinical whole-genome sequencing (cWGS) is twice as effective as usual care in diagnosing acutely ill newborns suspected of genetic conditions. The study involved 354 infants and demonstrated that access to cWGS significantly enhanced diagnostic rates and clinical management decisions. The trial's results advocate for broader implementation of cWGS, suggesting it may become a first-tier diagnostic tool for critically ill infants, thereby improving patient outcomes and healthcare strategies.
Illumina Ventures has closed its second investment fund, raising $325 million to enhance its capital to $560 million. The fund, primarily backed by Illumina, Inc. (NASDAQ: ILMN), aims to invest in innovative start-ups in healthcare, particularly in genomics and precision medicine. Since its inception in 2016, Illumina Ventures has invested in 25 companies, contributing to life science advancements. The firm plans to explore more ambitious projects in the US and Europe, reflecting its commitment to transforming healthcare.